Pay in 4 interest-free payments of $5.83 Learn more
Ships within 48 hours · Estimated delivery Sep 12 - Sep 17
Phase 5: Reintroduction & Maintenance The 21-day most important phase gradual food reintroduction with 1-week intervals
From topical research: Most commonly reported observation: mild transient redness at application site (attributed to vascular activity from VEGF stimulation) No systemic adverse events reported in human topical studies at standard concentrations No evidence of carcinogenicity or mutagenicity in available in vitro models From injectable research (preclinical): At supratherapeutic doses in animal models, mild injection site reactions have been noted No organ toxicity observed in standard preclinical safety panels No immunogenicity concerns identified (consistent with its endogenous structure) Copper considerations: GHK-Cu delivers a small amount of bioavailable copper
Nisamedtinov I, Kevvai K, Orumets K, Arike L, Sarand I, Korhola M, et al
This is compared to a 2.4% loss of weight in those taking a placebo
Animal data suggest BPC-157 modulates nitric oxide pathways and interacts with dopaminergic and serotonergic systems
Read clinical review Comparisons GHK-Cu + Epitalon Stack: When to Pick One Over the Stack A clinical guide to GHK-Cu and Epitalon individually and combined, mechanisms, dosing protocols, evidence quality, and a decision framework for choosing one peptide or the stack
US$ 20.38
US$ 28.39
US$ 24.33
